ANDA 40302, held by Hospira. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 40302 (Lidocaine Hydrochloride Preservative Free In Plastic Container), held by Hospira, was first approved by FDA on Sep 28, 1998, with 2 approved supplements and 0 published complete response letters.
Indications and Usage Lidocaine hydrochloride injection administered intravenously or intramuscularly, is specifically indicated in the acute management of ventricular arrhythmias such as those occurring in relation to acute myocardial infarction, or during cardiac manipulation, such as cardiac surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 28, 1998 | Original application | Approved |
| Lidocaine Hydrochloride Preservative Free In Plastic Container1% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Lidocaine Hydrochloride Preservative Free In Plastic Container2% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Mar 16, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 4, 2002 | Supplement 1Labeling | Approved | None posted |
| Sep 28, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters